Pharma — India Patent Cases
967 decisions indexed
Page 23 of 33 · 967 total
Novartis Ag v.Natco Pharma Limited
Novartis sought an interlocutory injunction against Natco Pharma Limited for allegedly infringing its suit patent (IN 233161) covering the drug Eltrombopag Olamine, marketed as REVOLADE. The defendant contested by questioning the patent's validity under Section 64 of the Patents Act. The court found that infringement was established and there was no prima facie case of vulnerability to revocation, thus granting the injunction.
Vifor (International) Ltd v.Alembic Pharmaceuticals Limited
Vifor (International) Ltd filed a suit against Alembic Pharmaceuticals Limited seeking permanent injunction and damages for infringing Vifor's patent. The parties subsequently reached an amicable settlement on August 9, 2021.
Eli Lilly And Company & Ors. v.Bryan Pharmaceuticals Through Its Proprietor Mr. Laxmi Kand Pal / Navneet Kand Pal & Ors.
In this pharmaceutical dispute, Eli Lilly sued several companies for marketing its patented compound Baricitinib under a brand name ('Barinat') for rheumatoid arthritis, allegedly breaching licensing agreements that restricted use solely to COVID-19 treatment. The court addressed an application by one defendant (Defendant No. 11), who claimed the marketing was an inadvertent error and no sales had occurred. After the defendant provided undertakings not to market or sell the drug for any ailment other than COVID-19, the plaintiff agreed that no cause of action survived against this specific defendant, leading to its removal from the suit.
Bristol-Myers Squibb Holdings Ireland Unlimited Company v.Zee Laboratories Limited & Ors.
The plaintiffs filed a suit seeking an ad interim injunction against the defendants for allegedly infringing Indian Patent Nos. 247381, which covers the subject matter related to Apixaban. The court granted the ad interim injunction, restraining the defendants from dealing in or advertising the infringing generic products 'Apixaz' and 'Apiquis', and ordered the permanent delisting of such advertisements.
Chugai Seiyaku Kabushiki Kaisha v.Hetero Labs Limited
Chugai Seiyaku Kabushiki Kaisha filed a suit seeking an ad interim injunction against Hetero Labs Limited for infringing Indian Patent No. IN 294424, which covers Alectinib or its salts/solvates. The court allowed the application subject to exceptions, permitting defendants to use the drug for research purposes under Section 107A of the Patents Act but prohibiting commercial launch without prior court permission.
Novartis AG v.Natco Pharma Limited
Novartis AG filed a suit alleging infringement of its Indian Patent No. 229051, which covers a pharmaceutical composition combining Valsartan and Sacubitril. The dispute centered on whether Natco Pharma Limited's product, described as a supra molecular complex, infringed the patented combination.
Galpha Laboratories Limited v.Shivansh Shrivastava
The Plaintiff, a pharmaceutical company, filed an opposition against the Defendant's application for the trade mark BFOLIN. The court examined the similarity between the established mark B-COLEN and the proposed mark BFOLIN. Satisfied that there is a prima facie case of likelihood of confusion, the court granted an ad-interim injunction.
Pfizer Inc & Ors v.Triveni Interchem Private Limited & Ors
The plaintiffs, holding patent IN 218291 for Palbociclib, filed an application seeking interim relief against the defendants who were allegedly manufacturing, marketing, and selling infringing products online. The court found prima facie evidence of infringement and passed several ad interim injunctions restraining the parties from further dealing in the patented product.
Merck Sharp And Dohme Corp & Anr v.Harman Finochem Limited
The plaintiffs filed a suit alleging that the defendant was violating and infringing their registered patent (IN 209816) related to Sitagliptin. Despite previous assurances, the plaintiffs presented evidence showing the defendant continued to advertise and export infringing products. The court granted an ex-parte ad interim injunction restraining the defendant from further infringement.
Bristol Myers Squibb Holdings Ireland Unlimited Company v.Triveni Interchem Private Limited
The plaintiffs filed a suit seeking an ad interim injunction against the defendants for dealing in generic Apixaban product that infringes Indian Patent No. 247381. The court, relying on previous orders regarding the same patent, passed an ex-parte ad-interim injunction restraining the defendants from manufacturing, selling, or distributing the infringing generic product.
Pfizer Inc v.Natco Pharma Limited
The court passed several orders regarding various interlocutory applications in the suit filed by Pfizer Inc against Natco Pharma Limited. Specifically, the court granted an undertaking to the defendant that they would provide four weeks prior notice before launching the drug alleged to infringe the patent.
Chugai Seiyaku Kabushiki Kaisha v.Fresenius Kabi Oncology Limited
Chugai Seiyaku Kabushiki Kaisha filed a suit seeking an ad interim injunction against Fresenius Kabi Oncology Limited for infringing Indian Patent No. IN 294424 related to the drug Alectinib. The court granted the injunction, restraining commercial activities, but allowed the defendant to use the product for research purposes under Section 107A of the Patents Act.
PFIZER INC v.NATCO PHARMA LIMITED
The plaintiffs (Pfizer Inc) informed the court that the present matter relates to Patent No. 218291 and is connected to several other pending cases involving the same patent. The court directed that the present matter be listed along with these related matters before the Judge In-charge on September 30, 2021.
Terrace Pharmaceuticals Pvt. Ltd. v.The Controller General Of Patents, Designs and Trademarks & Anr.
In this matter concerning a petition before the Delhi High Court, the court addressed several procedural applications. While certain motions were disposed of, the bench issued a critical direction requiring the petitioner to implead the actual registered proprietors of the trademark in question. This step is necessary because a favorable ruling could lead to the cancellation of their registered mark, ensuring all stakeholders are heard before proceeding with the core dispute.
Macleods Pharmaceuticals Limited v.Nava Healthcare Pvt. Ltd.
The Delhi High Court ruled in favor of Macleods Pharmaceuticals Limited, granting a permanent injunction against Nava Healthcare Pvt. Ltd. and associated defendants for trademark infringement and passing off. The court found that the Defendants' mark 'Blofin-D3 Max' and packaging were identical to the Plaintiff's registered marks ('Bio-D3', 'Bio-D3 Max') used for similar pharmaceutical preparations. Although Defendant No. 1 changed its mark, the injunction was upheld against all parties involved in the collaboration, and costs were awarded to the Plaintiff.
Alkem Laboratories Limited v.Danish Health Care Pvt Ltd & Anr.
The Delhi High Court decreed the suit filed by Alkem Laboratories Limited against Danish Health Care Pvt Ltd following an amicable settlement reached through court mediation. The dispute centered on the alleged infringement of Alkem’s registered trademark ‘ALDIGESIC’ in medicinal preparations. Under the terms of the settlement, the Defendants acknowledged Alkem's rights and agreed to cease using the infringing mark and similar trade dress, further agreeing to withdraw their own pending trademark application for 'ALGESIC'.
Eli Lilly And Company v.Hetero Labs Limited
The plaintiffs allege that the defendants have infringed their patent for Baricitinib by manufacturing and selling it without a license. The case involves a request for an injunction to prevent the defendants from continuing this activity.
Pfizer Inc v.Triveni Interchem Private Limited
The plaintiff alleges infringement of its Indian Patent No. 218291 related to Palbociclib, marketed under the brand name 'Palbace'. The court found a prima facie case of infringement but noted the timeline of alleged infringement was unclear.
Chugai Seiyaku Kabushiki Kaisha & Anr v.Natco Pharma Limited
Chugai Seiyaku Kabushiki Kaisha filed a suit seeking an ad interim injunction against Natco Pharma Limited, alleging infringement of Indian Patent No. IN 294424 concerning Alectinib. The court allowed the application subject to exceptions and noted that while the defendant could use the drug for research under Section 107A, any commercial launch would require prior permission from the court.
Chugai Seiyaki Kabushiki Kaisha v.MSN Laboratories Private Limited
The plaintiffs filed a suit seeking an ad interim injunction against MSN Laboratories Private Limited for infringing Indian Patent No. IN 294424, which covers Alectinib or its derivatives. The court allowed the application subject to exceptions, permitting the defendant to use the drug for research purposes under Section 107A of the Patents Act, but prohibiting commercial launch without prior court permission.
Sun Pharmaceuticals Industries Ltd v.Union Of India & Ors.
Sun Pharmaceuticals Industries Ltd filed a writ petition seeking directions for the expeditious disposal of opposition proceedings against Patent No. 257402, which was granted to Novo Nordisk A/S. The court addressed the procedural delay and directed the respondents to furnish the Opposition Board's recommendations within one week, subsequently rescheduling the hearing.
Novo Nordisk A/S v.Union Of India & Ors.
Novo Nordisk A/S filed a petition seeking a writ of mandamus to compel Respondent Authorities (No. 1 through No. 3) to decide on its request for the cross-examination of witnesses in a pending post-grant opposition against Patent No. IN 257402. The court, after considering arguments from both sides, directed that Respondent No. 2 fix the date for the cross-examination and complete it expeditiously.
Bristol-Myers Squibb Ireland Unlimited Company v.Micro Labs Limited
The plaintiffs filed a suit seeking permanent injunction against Micro Labs Limited for infringing their registered patent (No. 247381) related to Apixaban, an anticoagulant drug. The court considered the prior history of similar cases and granted an ex-parte ad- interim injunction restraining the defendant from manufacturing or selling generic Apixaban under any brand name, including 'APIVAS'.
Novartis Ag v.Msn Laboratories Pvt Ltd
The plaintiff, Novartis AG, seeks to restrain the defendant from manufacturing Pazopanib Hydrochloride, claiming it infringes their Indian patent. The defendant has obtained approval to manufacture the product, raising concerns of imminent patent infringement.
F.Hoffmann-La Roche Ltd. v.Matrix Laboratories Limited
F.Hoffmann-La Roche Ltd. filed a suit seeking permanent injunction against Matrix Laboratories Limited for infringing Indian Patent No.196774, which relates to a pharmaceutical or chemical compound product. The court ultimately disposed of the suit as no further orders were necessary due to the rejection of leave to institute the suit by the Division Bench.
Novartis Ag & Anr. v.Assistant Controller Of Patents And Designs
Novartis Ag & Anr. filed an appeal challenging the Assistant Controller's refusal to grant their Indian Patent Application No. 10611/DELNP/2015. The court allowed an interlocutory application regarding document filing and issued notice to the Defendant, setting the matter for further hearing.
Indiyaa Distribution Network Llp v.P Singh & Ors.
The Delhi High Court granted an ad-interim injunction in favor of Indiyaa Distribution Network Llp against P Singh & Ors. The Plaintiff, a prior user of the Ayurvedic joint pain relief oil 'SANDHI SUDHA', successfully argued that the Defendants' use of similar marks and imitation of packaging constituted passing off and copyright infringement. The court recognized the Plaintiff's established market presence and sales history to protect consumers from potential confusion.
Cadila Healthcare Limited v.Pure & Cure Healthcare Pvt. Ltd.
Cadila Healthcare Limited successfully concluded its trademark infringement suit against Pure & Cure Healthcare Pvt. Ltd. by reaching a comprehensive settlement agreement before the Delhi High Court. The defendants formally acknowledged Cadila's absolute proprietary rights in the 'AMLODAC' trademark and committed to ceasing all use of the mark, including recalling existing stock and destroying promotional materials. This resolution allows the suit to be disposed of with a decree reflecting the agreed-upon terms.
Sandeep Pandey v.Union Of India And 4 Others
The petitioner filed a PIL seeking directions for the vaccination of citizens between the ages of 18 and 45, and also sought directions under the Patents Act, 1970, to acquire necessary patents for vaccine manufacturing. The court dismissed the petition as the issue was pending before the Apex Court.
Merck Sharp And Dohme Corp. v.Sms Pharmaceuticals Limited
Merck Sharp And Dohme Corp. filed a suit seeking an injunction against Sms Pharmaceuticals Limited for infringing its patent on Sitagliptin, an anti-diabetic drug. The court initially granted an ex-parte ad interim injunction in favor of Merck. However, upon considering the defendant's request under Section 107A (Bolar exemption), the court modified the injunction to allow limited export of the API for research and development purposes.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.